Overall world revenue for Cancer Immunotherapy Market, 2024 to 2034 in terms of value the market will surpass US$135.0 billion in 2024, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
The Cancer Immunotherapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Modern cancer treatments, such as those based on immunotherapy, have revolutionised the field in recent years. One such treatment that has greatly excited researchers and oncologists is cancer immunotherapy. Globally, cancer immunotherapy is being used as a treatment for cancer after years of intensive research. For instance, the German biomedical research institute BioMed X and one of the biggest pharmaceutical corporations in Japan, Ono Pharmaceutical Co., Ltd., announced in December 2023 the commencement of a new cooperative research initiative. Using neutrophils' anticancer properties to create next-generation immunotherapies is the aim of this research endeavour. Therefore, the primary driver propelling the growth of this market is the ongoing research into how to improve immunotherapy and the ongoing development of novel immunotherapies for the treatment of cancer.
The Keytruda maker, Merck, states that the out-of-pocket expenses for each infusion might vary from $1,000 to $1,950. However, this rate can still be excessively expensive for many patients. In the event that the patient has Medigap or Medicare Advantage (Part C), additional coverage may be obtained. The Keytruda treatment may potentially be completely covered, depending on the plan. In actuality, 41% of patients with Medicare Advantage Plans reported having no out-of-pocket costs, according to Merck. Patients in developing nations cannot afford the high cost of immunotherapy medications. One of the main obstacles facing businesses developing immunotherapy medications is high pricing. Thus, it is one of the main factors impeding this market's growth over the predicted period.
The Cancer Immunotherapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Increasing Prevalence of Cancer and Increasing Research in Cancer Immunotherapy are driving the Market Growth
Cancer is a major cause of death worldwide, accounting for about 20 million new cancer cases and over 9 million deaths in 2022, according to data released by the World Health Organisation in February 2024. By 2040, the American Cancer Society, Inc. projects that the global cancer burden would have increased to over 28 million cases due to present and anticipated population ageing and growth. North America is fourth in terms of cancer deaths and fourth in terms of new cases, whereas China, which has the greatest population in the world, has the highest global proportion of both. The cancer burden may rise in the future due to factors such increased alcohol and tobacco use, poor diet, physical inactivity, and air pollution in many different parts of the world.Modern cancer treatments, such as those based on immunotherapy, have revolutionised the field in recent years. One such treatment that has greatly excited researchers and oncologists is cancer immunotherapy. Globally, cancer immunotherapy is being used as a treatment for cancer after years of intensive research. For instance, the German biomedical research institute BioMed X and one of the biggest pharmaceutical corporations in Japan, Ono Pharmaceutical Co., Ltd., announced in December 2023 the commencement of a new cooperative research initiative. Using neutrophils' anticancer properties to create next-generation immunotherapies is the aim of this research endeavour. Therefore, the primary driver propelling the growth of this market is the ongoing research into how to improve immunotherapy and the ongoing development of novel immunotherapies for the treatment of cancer.
Reimbursement Challenges, High Cost and Side-effects may Hamper Cancer Immunotherapy Growth
Healthcare providers, insurance companies, and national and local government organisations all around the world have faced difficulties in getting reimbursement for cancer immunotherapy treatments. Cancer immunotherapy is one of the priciest medications available, costing more than $100,000 per patient. This covers the price of medications, hospital stays, and multiple days of intensive care because many patients receiving cancer immunotherapy treatments have serious adverse effects.The Keytruda maker, Merck, states that the out-of-pocket expenses for each infusion might vary from $1,000 to $1,950. However, this rate can still be excessively expensive for many patients. In the event that the patient has Medigap or Medicare Advantage (Part C), additional coverage may be obtained. The Keytruda treatment may potentially be completely covered, depending on the plan. In actuality, 41% of patients with Medicare Advantage Plans reported having no out-of-pocket costs, according to Merck. Patients in developing nations cannot afford the high cost of immunotherapy medications. One of the main obstacles facing businesses developing immunotherapy medications is high pricing. Thus, it is one of the main factors impeding this market's growth over the predicted period.
Key Questions Answered
- How is the cancer immunotherapy market evolving?
- What is driving and restraining the cancer immunotherapy market?
- How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each cancer immunotherapy submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading cancer immunotherapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the cancer immunotherapy projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of cancer immunotherapy projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the cancer immunotherapy market?
- Where is the cancer immunotherapy market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Cancer Immunotherapy market today, and over the next 10 years:
- This 286-page report provides 117 tables, 189 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), impact of rising Cancer Immunotherapy prices and recent developments.
Segments Covered in the Report
Technology
- Monoclonal Antibodies
- Immunomodulators
- Other Technology
Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Others
End-users
- Hospitals
- Cancer Research Centres
- Clinics
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Switzerland
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Egypt
- Rest of MEA
Leading companies profiled in the report
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GSK plc
- Immunocore Ltd.
- Johnson & Johnson Services, Inc.
- Lilly
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited
How will the Cancer Immunotherapy Market, 2024 to 2034 report help you?
In summary, the 280+ page report provides you with the following knowledge:- Revenue forecasts to 2034 for Cancer Immunotherapy Market, 2024 to 2034, with forecasts for technology, application, end-users, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Cancer Immunotherapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Cancer Immunotherapy Market, 2024 to 2034.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Cancer Immunotherapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview1.1 Objectives of the Study
1.2 Introduction to Cancer Immunotherapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Prevalence of Cancer
3.3.1.2 Increasing Research in Cancer Immunotherapy
3.3.1.3 Increasing Funding for the Cancer Research by Government, Public and Private Sector
3.3.2 Market Restraining Factors
3.3.2.1 Reimbursement Challenges for Cancer immunotherapy
3.3.2.2 High Cost and Side-effects of Cancer Immunotherapy
3.3.3 Market Opportunities
3.3.3.1 Increased Focus towards Advanced Treatment Protocols
3.3.3.2 Significant Unmet Need in Cancer Diagnosis
3.3.3.3 Growing use of AI in Cancer immunotherapy Manufacturing
3.4 Supply Chain Analysis
3.5 Regulatory Framework
3.6 Emerging Markets and Megatrends
3.7 Porter’s Five Forces Analysis
3.7.1 Bargaining Power of Buyers (High)
3.7.2 Bargaining Power of Suppliers (Low)
3.7.3 Threat of New Entrants (Low)
3.7.4 Threat of Substitute Products (High)
3.7.5 Intensity of Competitive Rivalry (High)
3.8 PEST Analysis
4 Cancer Immunotherapy Market Analysis by Technology
4.1 Key Findings
4.2 Technology Segment: Market Attractiveness Index
4.3 Cancer Immunotherapy Market Size Estimation and Forecast by Technology
4.4 Monoclonal Antibodies
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Immunomodulators
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Other Technology
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Cancer Immunotherapy Market by Application
5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Cancer Immunotherapy Market, by Application
5.4 Lung Cancer
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Breast Cancer
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Colorectal Cancer
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Melanoma
5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Prostate Cancer
5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Head & Neck Cancer
5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
5.9.2 Market Share by Region, 2024 & 2034 (%)
5.10 Ovarian Cancer
5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
5.10.2 Market Share by Region, 2024 & 2034 (%)
5.11 Pancreatic Cancer
5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
5.11.2 Market Share by Region, 2024 & 2034 (%)
5.12 Others
5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
5.12.2 Market Share by Region, 2024 & 2034 (%)
6 Cancer Immunotherapy Market by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Cancer Immunotherapy Market by End-users Forecast, 2024-2034
6.4 Hospitals
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Cancer Research Centers
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Clinics
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
7 Cancer Immunotherapy Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
8 North America Cancer Immunotherapy Market Analysis
8.1 Key Findings
8.2 North America Cancer Immunotherapy Market Attractiveness Index
8.3 North America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
8.4 North America Cancer Immunotherapy Market Size Estimation and Forecast by Country
8.5 North America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
8.6 North America Cancer Immunotherapy Market Size Estimation and Forecast by Application
8.7 North America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
8.8 U.S. Cancer Immunotherapy Market Analysis
8.9 Canada Cancer Immunotherapy Market Analysis
9 Europe Cancer Immunotherapy Market Analysis
9.1 Key Findings
9.2 Europe Cancer Immunotherapy Market Attractiveness Index
9.3 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
9.4 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Country
9.5 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Technology
9.6 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Application
9.7 Europe Cancer Immunotherapy Market Size Estimation and Forecast by End-users
9.8 Germany Cancer Immunotherapy Market Analysis
9.9 UK Cancer Immunotherapy Market Analysis
9.10 France Cancer Immunotherapy Market Analysis
9.11 Italy Cancer Immunotherapy Market Analysis
9.12 Spain Cancer Immunotherapy Market Analysis
9.13 Switzerland Cancer Immunotherapy Market Analysis
9.14 Netherlands Cancer Immunotherapy Market Analysis
9.15 Rest of Europe Cancer Immunotherapy Market Analysis
10 Asia Pacific Cancer Immunotherapy Market Analysis
10.1 Key Findings
10.2 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
10.3 Asia Pacific Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Country
10.5 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Technology
10.6 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Application
10.7 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by End-users
10.8 Japan Cancer Immunotherapy Market Analysis
10.9 China Cancer Immunotherapy Market Analysis
10.10 India Cancer Immunotherapy Market Analysis
10.11 Australia Cancer Immunotherapy Market Analysis
10.12 South Korea Cancer Immunotherapy Market Analysis
10.13 South East Asia Cancer Immunotherapy Market Analysis
10.14 Rest of Asia Pacific Cancer Immunotherapy Market Analysis
11 Latin America Cancer Immunotherapy Market Analysis
11.1 Key Findings
11.2 Latin America Cancer Immunotherapy Market Attractiveness Index
11.3 Latin America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Country
11.5 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
11.6 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Application
11.7 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
11.8 Brazil Cancer Immunotherapy Market Analysis
11.9 Mexico Cancer Immunotherapy Market Analysis
11.10 Argentina Cancer Immunotherapy Market Analysis
11.11 Rest of Latin America Cancer Immunotherapy Market Analysis
12 MEA Cancer Immunotherapy Market Analysis
12.1 Key Findings
12.2 MEA Cancer Immunotherapy Market Attractiveness Index
12.3 MEA Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Country
12.5 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Technology
12.6 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Application
12.7 MEA Cancer Immunotherapy Market Size Estimation and Forecast by End-users
12.8 GCC Cancer Immunotherapy Market Analysis
12.9 South Africa Cancer Immunotherapy Market Analysis
12.10 Egypt Cancer Immunotherapy Market Analysis
12.11 Rest of MEA Cancer Immunotherapy Market Analysis
13 Company Profiles
13.1 Competitive Landscape, 2023
13.2 Strategic Outlook
13.3 F. Hoffmann-La Roche Ltd.
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2019-2023
13.3.3.2 R&D, 2019-2023
13.3.3.3 Segment Market Shares, 2023
13.3.3.4 Regional Market Shares, 2023
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 Merck & Co., Inc.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2019-2023
13.4.3.2 R&D, 2019-2023
13.4.3.3 Segment Market Shares, 2023
13.4.3.4 Regional Market Shares, 2023
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 Novartis AG
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2019-2023
13.5.3.2 R&D, 2019-2023
13.5.3.3 Segment Market Shares, 2023
13.5.3.4 Regional Market Shares, 2023
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 Bristol-Myers Squibb Company
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2019-2023
13.6.3.2 R&D, 2019-2023
13.6.3.3 Segment Market Shares, 2023
13.6.3.4 Regional Market Shares, 2023
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Bayer AG
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2019-2023
13.7.3.2 R&D, 2019-2023
13.7.3.3 Segment Market Shares, 2023
13.7.3.4 Regional Market Shares, 2023
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 AstraZeneca
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2019-2023
13.8.3.2 R&D, 2019-2023
13.8.3.3 Segment Market Shares, 2023
13.8.3.4 Regional Market Shares, 2023
13.8.4 Product Benchmarking
13.8.5 Strategic Outlook
13.9 Lilly
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2019-2023
13.9.3.2 R&D, 2019-2023
13.9.3.3 Regional Market Shares, 2023
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.10 Pfizer Inc.
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2019-2023
13.10.3.2 R&D, 2019-2023
13.10.3.3 Segment Market Shares, 2023
13.10.3.4 Regional Market Shares, 2023
13.10.4 Product Benchmarking
13.10.5 Strategic Outlook
13.11 Johnson & Johnson Services, Inc.
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2019-2023
13.11.3.2 R&D, 2019-2023
13.11.3.3 Segment Market Shares, 2023
13.11.3.4 Regional Market Shares, 2023
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 GSK plc
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2019-2023
13.12.3.2 R&D, 2019-2023
13.12.3.3 Segment Market Shares, 2023
13.12.3.4 Regional Market Shares, 2023
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook
13.13 Gilead Sciences, Inc.
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2019-2023
13.13.3.2 R&D, 2019-2023
13.13.3.3 Segment Market Shares, 2023
13.13.3.4 Regional Market Shares, 2023
13.13.4 Product Benchmarking
13.13.5 Strategic Outlook
13.14 Amgen Inc.
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2019-2023
13.14.3.2 R&D, 2019-2023
13.14.3.3 Regional Market Shares, 2023
13.14.4 Product Benchmarking
13.14.5 Strategic Outlook
13.15 AbbVie Inc.
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2019-2023
13.15.3.2 R&D, 2019-2023
13.15.3.3 Segment Market Shares, 2023
13.15.3.4 Regional Market Shares, 2023
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook
13.16 Immunocore Ltd.
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Financial Analysis
13.16.3.1 Net Revenue, 2019-2023
13.16.3.2 R&D, 2019-2023
13.16.3.3 Regional Market Shares, 2023
13.16.4 Product Benchmarking
13.16.5 Strategic Outlook
13.17 Sanofi
13.17.1 Company Snapshot
13.17.2 Company Overview
13.17.3 Financial Analysis
13.17.3.1 Net Revenue, 2019-2023
13.17.3.2 R&D, 2019-2023
13.17.3.3 Segment Market Shares, 2023
13.17.3.4 Regional Market Shares, 2023
13.17.4 Product Benchmarking
13.17.5 Strategic Outlook
13.18 Takeda Pharmaceutical Company Limited.
13.18.1 Company Snapshot
13.18.2 Company Overview
13.18.3 Financial Analysis
13.18.3.1 Net Revenue, 2019-2023
13.18.3.2 R&D, 2019-2023
13.18.3.3 Segment Market Shares, 2023
13.18.3.4 Regional Market Shares, 2023
13.18.4 Product Benchmarking
13.18.5 Strategic Outlook
14 Conclusion and Recommendations
14.1 Concluding Remarks
14.2 Recommendations for Market Players
List of Tables
Table 1 Cancer Immunotherapy Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Cancer Immunotherapy Market Forecast by Technology 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 3 Types of Monoclonal Antibodies
Table 4 Types of Monoclonal Antibodies and Approval Status
Table 5 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 6 Immunomodulators Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 7 Other Technology Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 8 Cancer Immunotherapy Market by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 9 Types of Monoclonal Antibodies
Table 10 Lung Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 11 Breast Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 12 Colorectal Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 13 Melanoma Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 14 Prostate Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 15 Head & Neck Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 16 Ovarian Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 17 Pancreatic Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 18 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 19 Cancer Immunotherapy Market by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 20 Hospitals Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 21 Cancer Research Centers Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 22 Clinics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 23 Cancer Immunotherapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 24 North America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 25 North America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 26 North America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 27 North America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 28 U.S. Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 29 Canada Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 30 Europe Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 31 Europe Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 32 Europe Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 33 Europe Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 34 Germany Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 35 UK Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 36 France Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 37 Italy Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 38 Spain Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 39 Switzerland Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 40 Netherlands Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 41 Rest of Europe Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 42 Asia Pacific Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 43 Asia Pacific Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 44 Asia Pacific Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 45 Asia Pacific Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 46 Japan Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 47 China Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 48 India Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 49 Australia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 50 South Korea Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 51 South East Asia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 52 Rest of Asia Pacific Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 53 Latin America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 54 Latin America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 55 Latin America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 56 Latin America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 57 Brazil Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 58 Mexico Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 59 Argentina Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 60 Rest of Latin America Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 61 MEA Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 62 MEA Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 63 MEA Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 64 MEA Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 65 GCC Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 66 South Africa Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 67 Egypt Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 68 Rest of MEA Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
Table 69 Strategic Outlook
Table 70 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 71 F. Hoffmann-La Roche Ltd. : Product Benchmarking
Table 72 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 73 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 74 Merck & Co., Inc.: Product Benchmarking
Table 75 Merck & Co., Inc.: Strategic Outlook
Table 76 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Novartis AG: Product Benchmarking
Table 78 Novartis AG: Strategic Outlook
Table 79 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Bristol-Myers Squibb Company: Product Benchmarking
Table 81 Bristol-Myers Squibb Company: Strategic Outlook
Table 82 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Bayer AG: Product Benchmarking
Table 84 Bayer AG: Strategic Outlook
Table 85 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 AstraZeneca: Product Benchmarking
Table 87 AstraZeneca: Strategic Outlook
Table 88 Lilly.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Lilly.: Product Benchmarking
Table 90 Lilly: Strategic Outlook
Table 91 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Pfizer Inc.: Product Benchmarking
Table 93 Pfizer Inc.: Strategic Outlook
Table 94 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Johnson & Johnson Services, Inc.: Product Benchmarking
Table 96 Johnson & Johnson Services, Inc.: Strategic Outlook
Table 97 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 GSK plc: Product Benchmarking
Table 99 GSK plc: Strategic Outlook
Table 100 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Gilead Sciences, Inc.: Product Benchmarking
Table 102 Gilead Sciences, Inc.: Strategic Outlook
Table 103 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Amgen Inc.: Product Benchmarking
Table 105 Amgen Inc.: Strategic Outlook
Table 106 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 AbbVie Inc.: Product Benchmarking
Table 108 AbbVie Inc.: Strategic Outlook
Table 109 Immunocore Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Immunocore Ltd.: Product Benchmarking
Table 111 Immunocore Ltd.: Strategic Outlook
Table 112 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Sanofi: Product Benchmarking
Table 114 Sanofi: Strategic Outlook
Table 115 Takeda Pharmaceutical Company Limited.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Takeda Pharmaceutical Company Limited.: Product Benchmarking
Table 117 Takeda Pharmaceutical Company Limited.: Strategic Outlook
List of Figures
Figure 1 Cancer Immunotherapy Market Segmentation
Figure 2 Cancer Immunotherapy Market Attractiveness Index by Region
Figure 3 Cancer Immunotherapy Market by Technology: Market Attractiveness Index
Figure 4 Cancer Immunotherapy Market by Application: Market Attractiveness Index
Figure 5 Cancer Immunotherapy Market by End-users: Market Attractiveness Index
Figure 6 Cancer Immunotherapy Market: Market Dynamics
Figure 7 Cancer Immunotherapy Market: Impact Analysis
Figure 8 Cancer Immunotherapy Industry: Supply Chain Analysis
Figure 9 Cancer Immunotherapy Market: Porter’s Five Forces Analysis
Figure 10 Cancer Immunotherapy Market: PEST Analysis
Figure 11 Cancer Immunotherapy Market by Technology: Market Attractiveness Index
Figure 12 Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %)
Figure 13 Cancer Immunotherapy Market Share Forecast by Technology, 2024, 2029, 2034 (%)
Figure 14 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 15 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 16 Immunomodulators Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 17 Immunomodulators Market Share Forecast by Region, 2024 & 2034 (%)
Figure 18 Other Technology Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 19 Other Technology Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Cancer Immunotherapy Market by Application: Market Attractiveness Index
Figure 21 Cancer Immunotherapy Market by Application, 2024-2034 (US$ Billion)
Figure 22 Cancer Immunotherapy Market Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 23 Lung Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 24 Lung Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Breast Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 26 Breast Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Colorectal Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 28 Colorectal Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Melanoma Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 30 Melanoma Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Prostate Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 32 Prostate Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Head & Neck Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 34 Head & Neck Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Ovarian Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 36 Ovarian Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Pancreatic Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 38 Pancreatic Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 40 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Cancer Immunotherapy Market by End-users: Market Attractiveness Index
Figure 42 Cancer Immunotherapy Market by End-users, 2024-2034 (US$ Billion)
Figure 43 Cancer Immunotherapy Market Share by End-users, 2024, 2029, 2034 (%)
Figure 44 Hospitals Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 45 Hospitals Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Cancer Research Centers Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 47 Cancer Research Centers Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Clinics Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 49 Clinics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Cancer Immunotherapy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 51 Cancer Immunotherapy Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 52 Cancer Immunotherapy Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 North America Cancer Immunotherapy Market Attractiveness Index
Figure 54 North America Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 55 North America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 56 North America Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 57 North America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %)
Figure 58 North America Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 59 North America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 60 North America Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
Figure 61 North America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
Figure 62 North America Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 63 U.S. Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 64 Canada Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 65 Europe Cancer Immunotherapy Market Attractiveness Index
Figure 66 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
Figure 67 Europe Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 68 Europe Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 69 Europe Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
Figure 70 Europe Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 71 Europe Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 72 Europe Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
Figure 73 Europe Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 74 Europe Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034(%)
Figure 75 Germany Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 76 UK Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 77 France Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 78 Italy Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 79 Spain Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 80 Switzerland Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 81 Netherlands Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 82 Rest of Europe Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 83 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
Figure 84 Asia Pacific Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 85 Asia Pacific Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 86 Asia Pacific Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 87 Asia Pacific Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
Figure 88 Asia Pacific Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 89 Asia Pacific Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 90 Asia Pacific Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
Figure 91 Asia Pacific Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 92 Asia Pacific Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 93 Japan Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 94 China Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 95 India Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 96 Australia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 97 South Korea Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 98 South East Asia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 99 Rest of Asia Pacific Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 100 Latin America Cancer Immunotherapy Market Attractiveness Index
Figure 101 Latin America Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 102 Latin America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 103 Latin America Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 104 Latin America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
Figure 105 Latin America Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 106 Latin America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 107 Latin America Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
Figure 108 Latin America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 109 Latin America Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 110 Brazil Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 111 Mexico Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 112 Argentina Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 113 Rest of Latin America Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 114 MEA Cancer Immunotherapy Market Attractiveness Index
Figure 115 MEA Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 116 MEA Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 117 MEA Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
Figure 118 MEA Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
Figure 119 MEA Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 120 MEA Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 121 MEA Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
Figure 122 MEA Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
Figure 123 MEA Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 124 GCC Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 125 South Africa Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 Egypt Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 Rest of MEA Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 128 Cancer Immunotherapy Market: Company Share/Ranking, 2023
Figure 129 F. Hoffmann-La Roche Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 130 F. Hoffmann-La Roche Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 131 F. Hoffmann-La Roche Ltd.: Segment Market Shares, 2023
Figure 132 F. Hoffmann-La Roche Ltd. Inc.: Regional Market Shares, 2023
Figure 133 Merck & Co., Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 134 Merck & Co., Inc.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 135 Merck & Co., Inc.: Segment Market Shares, 2023
Figure 136 Merck & Co., Inc.: Regional Market Shares, 2023
Figure 137 Novartis AG: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 138 Novartis AG: R&D, 2019-2023 (US$ Million, AGR %)
Figure 139 Novartis AG: Segment Market Shares, 2023
Figure 140 Novartis AG: Regional Market Shares, 2023
Figure 141 Bristol-Myers Squibb Company: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 142 Bristol-Myers Squibb Company : R&D, 2019-2023 (US$ Million, AGR %)
Figure 143 Bristol-Myers Squibb Company: Segment Market Shares, 2023
Figure 144 Bristol-Myers Squibb Company: Regional Market Shares, 2023
Figure 145 Bayer AG: Net Revenue, 2019-2023 (US$ Million, AGR (%)
Figure 146 Bayer AG: R&D, 2019-2023 (US$ Million, AGR %)
Figure 147 Bayer AG: Segment Market Shares, 2023
Figure 148 Bayer AG: Regional Market Shares, 2023
Figure 149 AstraZeneca: Net Revenue, 2019-2023 (US$ Million, AGR (%)
Figure 150 AstraZeneca: R&D, 2019-2023 (US$ Million, AGR %)
Figure 151 AstraZeneca: Segment Market Shares, 2023
Figure 152 AstraZeneca: Regional Market Shares, 2023
Figure 153 Lilly: Net Revenue, 2019-2023 (US$ Million, AGR (%)
Figure 154 Lilly: R&D, 2019-2023 (US$ Million, AGR %)
Figure 155 Lilly: Regional Market Shares, 2023
Figure 156 Pfizer Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 157 Pfizer Inc.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 158 Pfizer Inc.: Segment Market Shares, 2023
Figure 159 Pfizer Inc.: Regional Market Shares, 2023
Figure 160 Johnson & Johnson Services, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 161 Johnson & Johnson Services, Inc.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 162 Johnson & Johnson Services, Inc.: Segment Market Shares, 2023
Figure 163 Johnson & Johnson Services, Inc.: Regional Market Shares, 2023
Figure 164 GSK plc: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 165 GSK plc: R&D, 2019-2023 (US$ Million, AGR %)
Figure 166 GSK plc: Segment Market Shares, 2023
Figure 167 GSK plc: Regional Market Shares, 2023
Figure 168 Gilead Sciences, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 169 Gilead Sciences Inc.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 170 Gilead Sciences, Inc.: Segment Market Shares, 2023
Figure 171 Gilead Sciences, Inc.: Regional Market Shares, 2023
Figure 172 Amgen Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 173 Amgen Inc.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 174 Amgen Inc.: Regional Market Shares, 2023
Figure 175 AbbVie Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 176 AbbVie Inc.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 177 AbbVie Inc.: Segment Market Shares, 2023
Figure 178 AbbVie Inc.: Regional Market Shares, 2023
Figure 179 Immunocore Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 180 Immunocore Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
Figure 181 Immunocore Ltd.: Regional Market Shares, 2023
Figure 182 Sanofi: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 183 Sanofi: R&D, 2019-2023 (US$ Million, AGR %)
Figure 184 Sanofi: Segment Market Shares, 2023
Figure 185 Sanofi: Regional Market Shares, 2023
Figure 186 Takeda Pharmaceutical Company Limited: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 187 Takeda Pharmaceutical Company Limited: R&D, 2019-2023 (US$ Million, AGR %)
Figure 188 Takeda Pharmaceutical Company Limited: Segment Market Shares, 2023
Figure 189 Takeda Pharmaceutical Company Limited.: Regional Market Shares, 2023
Companies Mentioned
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GSK plc
- Immunocore Ltd.
- Johnson & Johnson Services, Inc.
- Lilly
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited
- Adaptimmune Therapeutics plc.
- Ambrx Biopharma
- Anima Biotech
- Arcellx, Inc.
- Astellas Pharma Inc.
- BELLUS
- Bicycle Therapeutics
- BigHat Biosciences
- BioMed X
- Biomunex Pharmaceuticals
- BioNex Solutions Inc.
- Blackford Analysis Ltd.
- Boehringer Ingelheim
- Calibr
- Caraway Therapeutics.
- Cellares
- CellVax Therapeutics
- Cerevel Therapeutics
- Chinook Therapeutics
- Cidara Therapeutics
- CinCor Pharma, Inc.
- Compugen
- CytoMed Therapeutics China
- Epicrispr Biotechnologies Inc.
- GE HealthCare
- Harpoon Therapeutics
- Horizon Therapeutics Plc.
- Immunoadoptive Cell Therapy Private Limited
- ImmunoGen
- Immunome, Inc.
- Inhibrx, Inc.
- Janssen-Cilag
- Karuna Therapeutics
- Landos Biopharma
- LIXTE Biotechnology Holdings
- Manaolana Oncology Inc.
- Mariana Oncology
- Merus
- Mirati Therapeutics, Inc.
- MorphoSys
- Neogene Therapeutics
- Nutcracker Therapeutics, Inc.
- Ono Pharmaceutical
- Panacea Venture
- Point Biopharma Global
- Prometheus Biosciences, Inc.
- Provention Bio, Inc.
- Qunol
- Sandoz
- Seagen Inc.
- Tentarix
- Tmunity Therapeutics, Inc.
- TScan Therapeutics
- Umoja Biopharma
- Xilio Therapeutics, Inc.
- XinThera LLC
- Advanced Research Projects Agency for Health (ARPA-H)
- Agência Nacional de Vigilância Sanitária (ANVISA)
- American Association for Cancer Research (AACR)
- American Institute for Cancer Research
- Australian Cancer Research Foundation (ACRF)
- Burroughs Wellcome Fund
- Canadian Cancer Society
- Central Drugs Standard Control Organisation (CDSCO)
- Centre for Biologics Evaluation and Research (CBER)
- Centre for Drug Evaluation and Research (CDER)
- Cima University of Navarra (Spain)
- Egyptian Foundation for Medical Sciences (EFMS)
- European donors and the Dutch Cancer Society (KWF)
- European Medicines Agency(EMA)
- Food and Drug Administration (FDA)
- German Cancer Research Centre (DKFZ)
- Global Cancer Observatory
- Globocan
- Indian Council of Medical Research (ICMR)
- Japanese Ministry of Health, Labour and Welfare (MHLW)
- Mayo Clinic Comprehensive Cancer Centre
- Ministry of Food and Drug Safety (MFDS)
- National Cancer Institute
- National Health Service (NHS)
- National Institutes of Health (NIH)
- National Medical Products Administration (NMPA)
- Netherlands Cancer Institute (NKI)
- Office of Biotechnology Products (OBP)
- Office of Cellular, Tissue, and Gene Therapies (OCTGT)
- Office of Haematology and Oncology Products (OHOP)
- Ontario Institute for Cancer Research (OICR)
- Spanish National Cancer Research Centre (CNIO)
- The Australian Precision Medicine Enterprise (APME)
- The Drug Controller General of India (DCGI)
- The European Commission (EC)
- The Institute of Cancer Research, London
- The International Society for Clinical Oncology (ISCO)
- The Medicines and Healthcare Products Regulatory Agency (MHRA)
- The US Cancer Research Institute
- Tohoku University
- UCLA Health Jonsson Comprehensive Cancer Centre
- University Medical Centre Mannheim (UMM)
- University of Texas
- UVA Cancer Centre
- Vanderbilt University Medical Centre
- Washington University School of Medicine
- World Health Organisation (WHO)
